Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Sahil Sekhon, Caleb Jeon, Mio Nakamura, Di Yan, Ladan Afifi, Tina Bhutani, Ethan Levin Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA Abstract: Psoriasis vulgaris is a chronic, immune-mediated systemic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sekhon S, Jeon C, Nakamura M, Yan D, Afifi L, Bhutani T, Levin E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	ixekizumab biologics psoriasis IL-17 anti-IL-17 Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/65c0789b2d8f4e359509330c849afc5f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:65c0789b2d8f4e359509330c849afc5f
record_format	dspace
spelling	oai:doaj.org-article:65c0789b2d8f4e359509330c849afc5f2021-12-02T01:00:24ZClinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis2230-326Xhttps://doaj.org/article/65c0789b2d8f4e359509330c849afc5f2017-11-01T00:00:00Zhttps://www.dovepress.com/clinical-utility-of-ixekizumab-in-the-treatment-of-moderate-to-severe--peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XSahil Sekhon, Caleb Jeon, Mio Nakamura, Di Yan, Ladan Afifi, Tina Bhutani, Ethan Levin Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA Abstract: Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affects ~7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate–severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab. Keywords: ixekizumab, biologics, psoriasis, IL-17, anti-IL-17 Sekhon SJeon CNakamura MYan DAfifi LBhutani TLevin EDove Medical PressarticleixekizumabbiologicspsoriasisIL-17anti-IL-17DermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 7, Pp 65-72 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	ixekizumab biologics psoriasis IL-17 anti-IL-17 Dermatology RL1-803
spellingShingle	ixekizumab biologics psoriasis IL-17 anti-IL-17 Dermatology RL1-803 Sekhon S Jeon C Nakamura M Yan D Afifi L Bhutani T Levin E Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
description	Sahil Sekhon, Caleb Jeon, Mio Nakamura, Di Yan, Ladan Afifi, Tina Bhutani, Ethan Levin Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA Abstract: Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affects ~7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate–severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab. Keywords: ixekizumab, biologics, psoriasis, IL-17, anti-IL-17
format	article
author	Sekhon S Jeon C Nakamura M Yan D Afifi L Bhutani T Levin E
author_facet	Sekhon S Jeon C Nakamura M Yan D Afifi L Bhutani T Levin E
author_sort	Sekhon S
title	Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
title_short	Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
title_full	Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
title_fullStr	Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
title_full_unstemmed	Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
title_sort	clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/65c0789b2d8f4e359509330c849afc5f
work_keys_str_mv	AT sekhons clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis AT jeonc clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis AT nakamuram clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis AT yand clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis AT afifil clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis AT bhutanit clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis AT levine clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis
_version_	1718403387941191680

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Ejemplares similares